Press Release Summary:
Enabling up to 192 transfection experiments to be performed in parallel, variable frequency magnefect-nano II DUO and fixed frequency magnefect-LT DUO offer gene transfection with optimized efficiencies and cell viabilities. Oscillating magnet arrays promote magnetic nanoparticle/DNA uptake into cells, and 2 x 6/24/96 well magnet array formats are interchangeable. Providing transfection times of less than 30 min, systems allow retransfection as well as adherent state transfection.
Original Press Release:
nanoTherics Launches Magnefect DUO Transfection Devices - New, Flexible Oscillating Magnet-Based Systems Enabling Improved Efficiencies and up to 192 Parallel Transfections
nanoTherics, a UK-based scientific medical research devices company, is pleased to announce launch of the magnefect-nano II DUO and the magnefect-LT DUO transfection systems which enable up to 192 transfection experiments to be performed in parallel.
These new, compact devices offer gene transfection with improved efficiencies and cell viabilities, even with a range of difficult cell types including neuronal and primary cells. They use a unique technology which applies oscillating magnet arrays to promote magnetic nanoparticle/DNA uptake into cells to improve non-viral gene transfection, whilst maintaining high cell viability. They are simple to use with low running costs (as low as $0.1 per transfection) providing improved transfection efficiency and effectiveness over the best currently available cationic lipids at short transfection times (<30 minutes). They allow retransfection as well as adherent state transfection for user flexibility. The magnefect-nano II DUO has been launched as a higher throughput version of the magnefect-nano II, which the Company introduced in September 2011, and provides full flexibility with interchangeable 2x6, 24 and 96-well magnet array formats and variable oscillating frequency capability to enable researchers to optimise protocols to maximise transfections specifically for the cell types they are using. The magnefect-LT DUO is a lower cost system which has been launched as a higher throughput version of the magnefect-LT, which the Company introduced in January 2011, with fixed frequency oscillating frequency and fixed 2x6-well or 2x24-well or 2x96-well magnet array formats.
Dr Linda E Cammish, Chief Executive Officer, said, "We are very pleased to add the magnefect-nano II DUO and the magnefect LT DUO to our product portfolio to enable our customers to not only improve transfection efficiencies with hard to transfect cells such as neuronal and primary cells but also to increase the throughput of the transfection experiments they are conducting". She added, "The systems have been designed as a direct result of customer feedback. They are compact systems with all of the advantages of the magnefect-nano II and the magnefect LT oscillating magnet assisted transfection devices such as the high transfection efficiencies and cell viabilities, short transfection times and low running costs but with higher though-put capability."
nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research conducted at Keele University and the University of Florida. The patented technology uses magnetic nanoparticles and oscillating magnetic fields to facilitate improved delivery of biomolecules, including DNA, into living cells. nanoTherics's gene transfection studies have shown significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst maintaining viability of transfected cells. These key attributes afford a significant competitive advantage over currently available systems. nanoTherics's primary business is supply of scientific devices and associated products which offer efficiency improvements to research laboratories in the pharmaceutical and biotechnology industries as well as academia. The medium to long-term opportunity for this approach relates to more effective non-viral gene therapy, an area demanding safer technology to treat genetic diseases and disorders including cancers, Parkinson's disease, multiple sclerosis and cystic fibrosis.